Autoantibody development is associated with clinical severity of COVID-19: A cohort study
Clinical Immunology,
Год журнала:
2025,
Номер
274, С. 110471 - 110471
Опубликована: Март 3, 2025
Язык: Английский
Animal models of post-acute COVID-19 syndrome: a call for longitudinal animal studies
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Фев. 26, 2025
Animal
models
are
indispensable
for
unraveling
the
mechanisms
underlying
post-acute
sequelae
of
COVID-19
(PASC).
This
review
evaluates
recent
research
on
PASC-related
perturbations
in
animal
models,
drawing
comparisons
with
clinical
findings.
Despite
limited
number
studies
post-COVID
conditions,
particularly
those
extending
beyond
three
months,
these
provide
valuable
insights.
Three
hallmark
features
PASC-lung
fibrosis,
hyperglycemia,
and
neurological
sequelae-have
been
successfully
replicated
paving
way
mechanistic
discoveries
future
medical
interventions.
Although
most
have
reported
conditions
within
14-60
days
post-infection,
they
still
offer
critical
reference
long-term
research.
also
explores
potential
persisting
immune
misfiring,
a
key
factor
chronicity
PASC
symptoms.
Moreover,
challenges
modeling
discussed,
including
genetic
diversity
inbred
strains
difficulties
accurately
identifying
PASC-affected
individuals.
To
address
issues,
we
propose
methodological
improvements,
such
as
comparing
individual
parameters
control
averages
incorporating
genetically
diverse
populations
like
collaborative
cross
models.
These
strategies
will
enhance
identification
characterization
endotypes
studies.
By
integrating
findings
from
manifestations
PASC,
can
more
insights
into
its
support
development
effective
therapeutic
strategies.
Finally,
emphasize
urgent
need
longitudinal
to
fully
uncover
driving
guide
interventions
mitigate
public
health
impact.
Язык: Английский
Type I Diabetes—A Rare Adverse Event Described in Patients Receiving Immunotherapy Versus a Side Effect from SARS-CoV-2 Infection
Raluca-Ileana Pătru,
Miruna Ghigeanu,
Maria-Alexandra Barbu
и другие.
Reports — Medical Cases Images and Videos,
Год журнала:
2025,
Номер
8(1), С. 31 - 31
Опубликована: Март 14, 2025
Introduction
and
Clinical
Significance:
Lung
cancer,
a
leading
cause
of
global
cancer
diagnoses,
maintains
the
highest
mortality
risk
despite
advances
in
treatment.
Immunotherapy
agents,
such
as
anti-programmed
death-1/programmed
death
ligand-1
(PD-1/PD-L1),
have
revolutionized
care
for
non-small
cell
lung
(NSCLC).
However,
success
is
tempered
by
emergence
immune-mediated
adverse
reactions,
including
rare
onset
type
I
diabetes.
The
incidence
diabetes
mellitus
increased
during
SARS-CoV-2
pandemic.
While
there
are
several
cases
new-onset
after
COVID-19
vaccination,
no
case
1
was
described
an
immune
checkpoint
inhibitor
(ICI)-treated
patient.
Case
Presentation:
A
57-year-old
male
with
stage
IV
NSCLC
(brain
liver
metastases)
who
had
been
treated
nivolumab
4
years
appeared
positive
infection
at
routine
check.
After
two
weeks,
he
admitted
to
our
clinic
severe
fatigue,
hyperglycemia,
hyponatremia,
hyperkalemia.
HbA1c
level
normal
serum
peptide
C
undetectable.
Nivolumab
treatment
ceased,
patient
became
fully
dependent
on
basal–bolus
insulin.
3
months,
showed
complete
imagistic
remission.
Conclusions:
presented
significant
challenges
due
unclear
etiology
newly
uncommon
age
which
developed.
outcome
suggests
that
anti-PD-1
can
act
synergistically.
Язык: Английский
Type 1 diabetes risk and severity after SARS-CoV-2 infection or vaccination
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Июль 4, 2024
Abstract
Aim
To
clarify
whether
SARS-CoV-2
infection
or
vaccination
contribute
to
risk
of
type
1
diabetes
more
severe
onset
in
children
and
young
adults.
Methods
We
analysed
cohorts
population-wide
registries
individuals
from
Norway
(N=1,986,970)
Sweden
(N=2,100,188).
used
regression
models
estimate
adjusted
rate
ratios
(aRR),
treating
exposures
as
time-varying,
starting
30
days
after
registered
positive
test
vaccination.
Findings
Pooled
results
age-groups
12-17
18-29
years
showed
no
significant
increase
documented
infections
(aRR
1.06,
95%CI:0.77-1.45).
There
was
moderate
heterogeneity,
with
a
suggestive
increased
among
infection.
for
association
between
1.09,
95%CI:
0.81,
1.48).
primarily
driven
by
an
inverse
adults
Sweden.
While
the
incidence
ketoacidosis
decreased
over
time
during
2016-2023,
break
time-trends
were
seen
March
2020
HbA1c,
severity
diabetic
ketoacidosis,
islet
autoantibodies,
at
diagnosis
diabetes.
Interpretation
Taken
together,
these
do
not
indicate
any
consistent,
large
effects
-vaccination
on
disease
onset.
Suggestive
associations
sub-groups
should
be
investigated
further
other
studies.
Funding
The
work
done
part
regular
institutions
where
authors
had
their
primary
affiliation,
specific
funding
obtained
Язык: Английский
COVID-19 – a Five-Year Update
ImmunoAnalysis,
Год журнала:
2024,
Номер
4, С. 10 - 10
Опубликована: Окт. 20, 2024
Background:
This
review
aims
to
categorically
describe
novel
advancements
our
understanding
and
management
of
COVID-19
associated
short-
long-term
sequelae
such
as
Long
COVID.
Methods:
Indexing
services
(Scopus
PubMed)
were
used
identify
pertinent
studies,
prioritizing
original
research,
meta
reviews
updated
institutional
guidelines
from
2022
onwards.
Papers
not
published
in
English
(or
where
full-text
translation
was
available),
those
skewed
terms
gender
distribution
participants,
conducted
on
non-human
populations
proposal
opinion
papers
excluded.
For
the
purposes
this
paper,
COVID
taken
mean
persistence
symptoms
longer
than
8
weeks
after
an
acute
infection.
After
deduplication,
application
exclusion
criterion
checking
for
relevance,
52
sources
identified
review.
The
keywords
literature
search
COVID-19,
COVID,
Chronic
SARS-CoV-2.
Results:
New
variants
challenge
vaccine
efficacy,
highlighting
socioeconomic
disparities
vaccination
rates.
exhibits
complex
symptoms,
including
cognitive
decline
physical
health
impacts.
virus’s
affinity
ACE-2
receptors
suggests
broader
implications,
reproductive
metabolic
disorders.
can
cause
a
drop
IQ
proportional
severity
disease
experienced.
Conclusion:
COVID-19’s
multifaceted
impacts
necessitate
ongoing
research
targeted
interventions.
Addressing
disparities,
updating
formulations,
effects
are
crucial.
Equitable
healthcare
policies
essential
mitigate
global
threat
inform
future
strategies.
Язык: Английский